Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) to $15 from $14 while maintaining a Buy rating. The firm sees the affordable medicines theme staying attractive in 2026.
In a separate development, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) and mAbxience announced on December 22 that the U.S. Food and Drug Administration approved its Biologics Licensing Applications for Boncresa™, a biosimilar referencing Prolia®, and Oziltus™, a biosimilar referencing XGEVA®. Denosumab is a monoclonal antibody widely used across oncology and osteoporosis-related conditions and is known to inhibit bone resorption. Amneal Pharmaceuticals, Inc.’s (NASDAQ:AMRX) partnership with mAbxience entails that the former holds exclusive U.S. commercialization rights while the latter is responsible for manufacturing and development.
Chirag and Chintu Patel, Co-Chief Executive Officers of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), stated that the addition of two denosumab biosimilars has expanded the company’s portfolio to five commercial biosimilars, bolstering its position in the rapidly developing domain. Management views biosimilars as a considerable long-term growth vector in the company’s Affordable Medicines segment.
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a medicine company that provides pharmaceuticals. The company’s product portfolio encompasses biosciences, specialty, generics, and product catalog. Its operations are divided into the Generics, Specialty, and AvKARE segments.
While we acknowledge the potential of AMRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
